Verona Pharma - Articles and news items

Verona secures funding commitments to help progress RPL554

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Verona Pharma has successfully secured funding commitments to raise gross proceeds of ¬£44.7m through a conditional placing with new and existing investors…

Positive Phase IIa study data for RPL554 in COPD

Industry news / 10 May 2016 / Victoria White, Digital Content Producer

RPL554 is a novel inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule…

Verona Pharma announces positive headline data from RPL554 trial

Industry news / 15 March 2016 / Victoria White

The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients…

Verona Pharma starts RPL554 Phase IIa combination study

Industry news / 14 October 2015 / Victoria White

Verona Pharma has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for COPD…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+